Capsugel's Bram Baert and Sandrine Picco argue that chasing zero nitrite in pharmaceutical excipients is often impractical and costly. They recommend setting scientifically justified, risk-based limits and consistently staying below them.
News|Articles|August 1, 2004
- Pharmaceutical Technology-08-01-2004
- Volume 2004 Supplement
- Issue 5
2004 Outsourcing Survey: Growing Demand for Services and Performance
Author(s)Jim Miller
Data from the 2004 Outsourcing Survey indicate that pharmaceutical companies are spending more on outsourced drug development, but with fewer suppliers.
Advertisement
Articles in this issue
Advertisement
Related to this article
Swedish biotech companies have a broad and varied product pipeline that is attracting attention from venture capitalists and pharmaceutical companies.
Andrew Parker, PhD, executive drug development consultant, Quotient Sciences, explains how AI is integrated into pharmaceutical development.
Advertisement
Advertisement